COVID-19 Update: All AMP Locations are open, see how we are offering safe in person care and virtual visits. Click here to Learn more about Virtual Care Options.

Click here for additional COVID-19 Information

Non-Discrimination Notice

Merck 010

Merck 010- A Phase 3, Randomized Open-label study of Pembrolizumab plus Olaparib versus Abiraterone Acetate or Enzalutamide


Patients who are unselected for HRR defects and have failed prior treatment w/one NHA AND Chemotherapy.

Sponsored by: Merck
Enrollment: Open

Please contact one of our Clinical Research Coordinators today to find out more information if you are interested in this trial.

Research Department (315) 478-4185, option 3